- Company
- Sales of Statin/Ezetimibe have surpassed ₩600 billion
- by Chon, Seung-Hyun Feb 3, 2022 05:57am
- In the dyslipidemia treatment market, a combination of Statin + Ezetimibe is gaining explosive popularity. The annual prescription market has more than quadrupled over the past five years, exceeding 600 billion won. Rosuvastatin +Ezetimibe is leading the market growth. According to UBIST, a pharmaceutical research institute, the amount of outpa
- Company
- Hepatitis C market in decline due to superior treatment
- by Ji Yong Jun Feb 3, 2022 05:56am
- The hepatitis C treatment market had contracted for two consecutive years since 2020. The annual decline in the number of hepatitis C patients and the introduction of effective drugs is analyzed to have caused the contraction. According to the market research institution UBIST on the 29th, outpatient prescription of hepatitis C treatments rec
- Company
- Competition in the narcolepsy tx market is expected
- by Eo, Yun-Ho Feb 3, 2022 05:56am
- Competition for prescription of drugs that prevent sleepiness and manage so-called narcolepsy has begun. According to related industries, competition with Teva Handok's Nuvigil (Armodafinil) is expected as Wakix (Pitolisant) of Mitsubishi Tanabe Pharma will be applied from next month (February). Wakix is a counteractive and antagonist that se
- Company
- An unexpected story by Organon and Viatris
- by Jan 28, 2022 05:58am
- Organon and Viatris' patent expired drugs remain powerful. Although questions have been raised about the growth engines of the two independent corporations after receiving "old drugs" from MSD and Pfizer, it is evaluated that it is as good as in Korea. ◆Organon's Atozet and Cozaar's outpatient prescription is 250 billion won Accordi
- Company
- The NOAC market with ₩230 billion is fluctuating
- by Kim, Jin-Gu Jan 27, 2022 05:44am
- The NOAC market, which has grown to 230 billion won, has fluctuated due to generic drugs. After the Supreme Court ruling, Eliquis enjoyed reflective benefits as generics were withdrawn altogether. On the other hand, in the case of Xarelto, as generic products were released one after another due to the expiration of material patents, it seems
- Company
- Celltrion completes transfer of Takeda-acquired products
- by Ji Yong Jun Jan 27, 2022 05:43am
- The transfer of rights for Takeda Pharmaceutical’s products that Celltrion acquired is now complete. The license of OTCs and diabetes drugs that were sold under Takeda Pharmaceutical’s name has been changed to Celltrion Pharm. According to the industry on the 26th, the ownership of the license for Nesina Act Tab 12.5/30mg has been chang
- Company
- Sales of flu treatments have decreased significantly
- by Chon, Seung-Hyun Jan 27, 2022 05:42am
- The outpatient prescription market also fluctuated two years after the landing of COVID-19. Sales in the pharmaceutical market, which is mainly used for infectious diseases such as influenza (flu) treatments, antibiotics, and expectorants, have decreased significantly. The flu treatment market has virtually disappeared. According to UBIST on
- Company
- KRPIA presidents will meet with Lee Joon-seok
- by Eo, Yun-Ho Jan 26, 2022 05:57am
- Ahead of the presidential election, KRPIA and multinational pharmaceutical presidents will meet with the leader of the main opposition party. According to the Dailypharm's confirmation, the presidents of the KRPIA will hold a meeting with Lee Joon-seok, CEO of People's Power, tomorrow morning (27th). The meeting will be attended by Oh Dong
- Company
- Outpatient prescriptions slow for MNCs...Viatris in the lead
- by Jan 26, 2022 05:57am
- Outpatient prescription sales of multinational pharmaceutical companies in Korea had slowed down in general last year. Viatris held the lead among multinational pharmaceutical companies for two consecutive years, but its amount of prescriptions also decreased 0.3% compared to the previous year. The top prescription drug companies such as MSD (Or
- Company
- SK Bioscience wins 3rd EU-GMP for its vaccine plant
- by Ji Yong Jun Jan 26, 2022 05:57am
- SK Bioscience, which has signed a CMO deal to manufacture the Novavax vaccine, has additional received EU-GMP certification from the European Medicines Agency. This is the third EU-GMP certification the company received. On the 25th, SK Bioscience announced that it had received additional EU-GMP certification for the manufacturing facilit
